Efficacy of Pegamotecan (PEG-Camptothecin) in Localized or Metastatic Cancer of the Stomach or Gastroesophageal Junction
Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and efficacy of pegamotecan
(PEG-camptothecin) in patients with pathologically-diagnosed locally advanced or metastatic
adenocarcinoma of the stomach or gastroesophageal junction who have relapsed or progressed
following one prior chemotherapy treatment regimen.